We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$395M
Cap. Flow %
-10.28%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
7.4 quarters

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD icon
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW icon
WW International
WW
+$487M
2
BPMC icon
Blueprint Medicines
BPMC
+$13.9M
3
ONC icon
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 46.31%
2 Consumer Discretionary 28.3%
3 Miscellaneous 25.15%
4 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BABA icon
51
Alibaba
BABA
$277B
$10.7M 0.28%
+65,000
New +$11.5M
2018 Q3
0 quarters
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$10.9B
$10.7M 0.28%
50,000
– –
2018 Q1
2 quarters
SLDB icon
53
Solid Biosciences
SLDB
$737M
$10.6M 0.28%
15,000
-1,667
-10% -$1.05M
2018 Q1
2 quarters
NIO icon
54
NIO
NIO
$8.97B
$10.5M 0.27%
+1,500,000
New +$12.4M
2018 Q3
0 quarters
BOLD icon
55
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.9M 0.26%
250,000
+14,000
+6% +$522K
2017 Q3
4 quarters
RCKT icon
56
Rocket Pharmaceuticals
RCKT
$281M
$9.85M 0.26%
400,000
– –
2018 Q1
2 quarters
LRMR icon
57
Larimar Therapeutics
LRMR
$277M
$9.35M 0.24%
66,667
-33,333
-33% -$4.05M
2016 Q4
7 quarters
CBAY icon
58
DELISTED
Cymabay Therapeutics
CBAY
$8.86M 0.23%
800,000
– –
2018 Q1
2 quarters
ALNY icon
59
CALL
Alnylam Pharmaceuticals
ALNY
$31.1B
$8.75M 0.23%
100,000
– –
2018 Q2
1 quarter
RNAC icon
60
Cartesian Therapeutics
RNAC
$213M
$8.73M 0.23%
18,718
+2,051
+12% +$824K
2018 Q1
2 quarters
IOVA icon
61
Iovance Biotherapeutics
IOVA
$6.62B
$7.88M 0.2%
700,000
– –
2018 Q1
2 quarters
CMTA
62
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$7.72M 0.2%
692,000
+492,000
+246% +$5.18M
2018 Q1
2 quarters
ACET icon
63
Adicet Bio
ACET
$52.5M
$7.57M 0.2%
4,464
-447
-9% -$583K
2018 Q1
2 quarters
REPL icon
64
Replimune Group
REPL
$1.26B
$7.25M 0.19%
+450,000
New +$7.89M
2018 Q3
0 quarters
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
$6.64M 0.17%
400,000
– –
2017 Q1
6 quarters
DRNA
66
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.49M 0.17%
425,000
– –
2018 Q1
2 quarters
SPRO icon
67
Spero Therapeutics
SPRO
$69.9M
$6.31M 0.16%
600,000
+250,000
+71% +$2.9M
2017 Q4
3 quarters
YI icon
68
111 Inc
YI
$27.7M
$6.08M 0.16%
+45,000
New +$6.29M
2018 Q3
0 quarters
ACIU icon
69
AC Immune
ACIU
$249M
$6M 0.16%
750,000
+150,000
+25% +$1.51M
2016 Q3
8 quarters
TBIO icon
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$6M 0.16%
600,000
+100,000
+20% +$1.16M
2018 Q2
1 quarter
AGEN icon
71
Agenus
AGEN
$346M
$5.88M 0.15%
140,113
– –
2013 Q2
21 quarters
LOGM
72
DELISTED
LogMein, Inc.
LOGM
$5.79M 0.15%
+65,000
New +$5.88M
2018 Q3
0 quarters
CRNX icon
73
DELISTED
Crinetics Pharmaceuticals
CRNX
$5.73M 0.15%
+200,000
New +$5.94M
2018 Q3
0 quarters
TECX icon
74
Tectonic Therapeutic
TECX
$456M
$5.19M 0.13%
8,333
-2,084
-20% -$924K
2018 Q2
1 quarter
SGMO icon
75
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.08M 0.13%
300,000
+100,000
+50% +$1.52M
2018 Q1
2 quarters
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $395M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.